✦ LIBER ✦

The effects of ritonavir and lopinavir/ritonavir on the pharmacokinetics of a novel CCR5 antagonist, aplaviroc, in healthy subjects

✍ Scribed by Kimberly K. Adkison; Anne Shachoy-Clark; Lei Fang; Yu Lou; Vicky R. Otto; M. Michelle Berrey; Stephen C. Piscitelli

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Antiviral activity and safety of aplavir

✍ P Yeni; A LaMarca; D Berger; P Cimoch; A Lazzarin; P Salvato; FM Smaill; E Teofi 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 233 KB

Effect of ritonavir on the pharmacokinet

✍ Natascia Corti; Antje Heck; Katharina Rentsch; Walter Zingg; Alexander Jetter; B 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 194 KB

Assessment of the pharmacokinetics, safe

✍ Samantha Abel; Elna Van Der Ryst; Maria C. Rosario; Caroline E. Ridgway; Christi 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 984 KB

Effect of efavirenz treatment on the pha

✍ C. J. L. La Porte; M. J. A. De Graaff-Teulen; E. P. H. Colbers; D. S. Voncken; S 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB

An integrated pharmacokinetic model for

✍ Rob ter Heine; Robert A. B. Van Waterschoot; Ron J. Keizer; Jos H. Beijnen; Alfr 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 267 KB

Absence of circadian variation in the ph

✍ R. P. G. Van Heeswijk; M. Bourbeau; I. Seguin; P. Giguere; G. E. Garber; D. W. C 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 166 KB